Dantrolene reduces platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice

Biochem Biophys Res Commun. 2022 Oct 1:623:51-58. doi: 10.1016/j.bbrc.2022.07.038. Epub 2022 Jul 16.

Abstract

Dantrolene is a ryanodine receptor blocker that is used clinically for treatment of malignant hyperthermia. This study was conducted using murine aortic vascular smooth muscle cells (MOVAS) and a mouse arterial injury model to investigate the inhibitory effect of dantrolene on smooth muscle cell proliferation and migration. We investigated whether dantrolene suppressed platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell proliferation and migration in vitro. The effect of dantrolene on smooth muscle phenotype was evaluated using immunostaining. In addition, smooth muscle cell proliferation and phenotype switching were tested by applying dantrolene around blood vessels using a mouse arterial injury model. Dantrolene inhibited PDGF-induced cell proliferation and migration of MOVAS. Dantrolene also inhibited the switch from contractile to synthetic phenotype both in vitro and in vivo. Dantrolene is effective at inhibiting vascular smooth muscle cell proliferation, migration, and neointimal formation following arterial injury in mice.

Keywords: Dantrolene; Vascular smooth muscle cell.

MeSH terms

  • Animals
  • Cell Movement
  • Cell Proliferation
  • Cells, Cultured
  • Dantrolene / pharmacology
  • Disease Models, Animal
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Smooth, Vascular* / metabolism
  • Myocytes, Smooth Muscle / metabolism
  • Neointima / pathology
  • Platelet-Derived Growth Factor / metabolism
  • Platelet-Derived Growth Factor / pharmacology
  • Vascular System Injuries* / drug therapy
  • Vascular System Injuries* / pathology

Substances

  • Platelet-Derived Growth Factor
  • Dantrolene